Deltex Medical Group PLC Major New US Hospital Account (0638C)
January 17 2018 - 2:00AM
UK Regulatory
TIDMDEMG
RNS Number : 0638C
Deltex Medical Group PLC
17 January 2018
17 January 2018
Deltex Medical Group plc
("Deltex Medical", "Deltex" or "the Company")
Major new US hospital account
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), is pleased to announce the
addition of a major new hospital in the USA.
The hospital is a University Teaching Hospital in our
Mid-Atlantic sales territory and the flagship site within a six
hospital healthcare system. It is ranked amongst the top ten
hospitals in the USA.
The hospital evaluated ODM thoroughly in 150 patients undergoing
either colorectal or urology surgery in November and December 2016.
In colorectal surgery, where it had already established all other
key aspects of a multi-disciplinary enhanced recovery surgical
programme, it demonstrated around a 10% reduction in mean length of
hospital stay. In urology surgery it demonstrated a c. 20%
reduction in mean length of hospital stay. The clinicians leading
the quality improvement project informed the Company that a
previous evaluation of an alternative cardiac output monitoring
technology to guide fluid management had, in contrast, shown an
increased length of stay.
The flagship hospital has now started implementing ODM into its
standard operating procedures for both colorectal and urological
surgery. The clinicians leading the implementation programme have
informed the Company that they expect this to lead to use of 40 to
50 probes a month; furthermore, that the system plans to introduce
ODM into the two largest sister hospitals in Q2 2018 and the
remaining three hospitals by Q4 2018 by which time the flagship
hospital expects to have started to roll ODM usage out into other
surgical disciplines. The Company is supporting the implementation
from its existing resources with no additional overhead.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"This is a strategically important account win for Deltex in an
important teaching hospital. Successful implementation through the
hospital and wider system should help drive our overall US sales
growth as well as providing an additional highly rated reference
account.
"The results from the hospital's evaluation validate the value
our ODM technology offers even in those hospitals that have the
very best patient outcomes. It is noteworthy that this US hospital
was able to use ODM to improve its patients' recoveries even though
its starting points for lengths of stay for these types of surgery
were already around half the NHS England average."
For further information, please contact:-
Deltex Medical Group 01243 774 837
plc investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief
Executive
Jonathan Shaw, Group
Finance Director
Nominated Adviser &
Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Ciaran Walsh
Joint Broker
Turner Pope Investments 0203 621 4120
(TPI) Ltd info@turnerpope.com
Andy Thacker
Financial Public Relations
IFC Advisory Ltd 0203 053 8671
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's proprietary ODM is the only
technology to measure blood flow in the central circulation in real
time. Minimally invasive, easy to set up and quick to focus, the
technology generates a low-frequency ultrasound signal, which is
highly sensitive to changes in flow and measures them immediately.
Deltex has been the only company in the enhanced haemodynamic space
to build a robust and credible evidence base proving the clinical
and economic benefits of its core technology, ODM which is proven
to reduce complications suffered by patients after surgery and save
hospitals the costs of treating those complications.
Deltex Medical's CardioQ-ODM+ platform also now provides
clinicians with two further advanced haemodynamic monitoring
technologies. High Definition Impedance Cardiography is an entirely
non-invasive monitoring technology which creates an electrical
field across the chest and measures the disruption to this field
when the heart pumps blood. Pulse Pressure Waveform Analysis uses
peripheral blood pressure signal analysis to give doctors
information on changes in the circulation and is particularly
suited to monitoring lower risk or haemodynamically stable
patients.
Company goal
Haemodynamic management is now becoming widely accepted as an
important major new medical modality. Consequently, the Company's
focus is on maximising value from the opportunities presented as
enhanced haemodynamic management is adopted into routine clinical
practice around the world. The Company aims to provide clinicians
with a single platform, a 'haemodynamic workstation', which offers
them a range of technologies from simple to sophisticated to be
deployed according to the patient's condition and skill and
expertise of the user. Doing this will enable the Company to
partner healthcare providers to support modern haemodynamic
management across the whole hospital.
The Company is currently in the implementation phase of
achieving this goal in a number of territories worldwide, operating
directly in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTMMGMMRVNGRZM
(END) Dow Jones Newswires
January 17, 2018 02:00 ET (07:00 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2023 to Apr 2024